Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Aravive Announces Initial Results From Phase 1b Portion Of Phase1b/2 Study Of AVB-500 In Combination With Cabozantinib In Clear Cell Renal Carcinoma; Says Was Well Tolerated And Co. Plans To Expand Dosing To Three Additional Patients

Aravive Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced positive initial results from the Phase 1b portion of its Phase 1b/2

ARAV